OCUL - Company ID 0001393434
The table below shows OCULAR THERAPEUTIX, INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$204.88M | -$134.68M | -$70.23M | -$59.60M | -$65.55M | -$53.55M |
| Capital expenditure | $12.01M | $1.29M | $6.09M | $3.71M | $1.19M | $841.00K |
| Investing cash flow | -$11.88M | -$1.29M | -$6.09M | -$3.71M | -$1.19M | -$841.00K |
| Dividends paid | - | - | - | - |
OCULAR THERAPEUTIX, INC reported operating cash flow of -$204.88M for fiscal year 2025. That is down 52.1% from -$134.68M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$34.00M (FY 2016) to -$204.88M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $561.72M | $332.11M | $169.83M | $1.45M | $2.85M | $228.01M |